Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Ioversol is a diagnostic contrast agent used in various medical imaging procedures, such as angiography, urography, and computed tomographic scans. Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues.
- Mechanism
- Curator reviewed · 3 references
Ioversol is a highly soluble non-ionic ionidated contrast agent. Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, allowing the radiographic visualization of the internal structures until significant hemodilution occurs. In imaging procedures, ioversol diffuses from the vascular to the extravascular space. In brains with an intact blood-brain barrier, this agent does not diffuse to the extravascular space. However, in patients with a disrupted blood-brain barrier, ioversol accumulates in the interstitial space of the disrupted region. As the product Optiray, ioversol enhances computed tomographic imaging through augmentation of radiographic efficiency with the degree of density enhancement directly related to the iodine content in an administered dose.
- Primary indication
- As the product Optiray 300, the intra-arterial use of ioversol is indicated for cerebral arteriography and peripheral arteriography in adults, while its intravenous use is indicated for CT imaging of the head and body, venography,...Curator reviewed · 13 structured indications
- Formula / weight
- C18H24I3N3O9 · 807.115 g/mol (avg)
- First approval
- Canada, 2002 · United States, 2007
- Also known as
- Optiray
- Code names
- MP-328
- Brand names
- Optiray
Resolves to
AMDBBAQNWSUWGN-UHFFFAOYSA-NSMILESOCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1IWhat you can answer from here — as of September 13, 2026
Which other approved drugs treat the same conditions as Ioversol, and which companies have late-stage candidates in those indications?